In addition, sensitivity analyses confirm that our estimate of the overall HR of recurrence-free survival, progression-free survival, cancer-specific survival and overall survival by survivin status is robust when IHC was chosen for the method for determination of survivin expression (Table 4). The gene discussed is BIRC5; the disease is cancer.